BEZ235 (NVP-BEZ235, Dactolisib) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。 在 3T3TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

NVP-BEZ 235；BEZ-235；BEZ 235；NVP-BEZ235；Dactolisib

White powder

DMF ：18 mg/mL warmed (38.33 mM)

DMSO : 5.2 mg/mL (11.07 mM; Need ultrasonic and warming)

p110α；p110γ；mTOR (p70S6K)；p110δ；ATR

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. BEZ235 is an mTORC1/2 catalytic inhibitor.

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies.

[1] Maira SM, et al. Mol Cancer Ther, 2008, 7(7), 1851-1863.

[2] Roper J, et al. PLoS One, 2011, 6(9), e25132.

[3] Roulin D, et al. Mol Cancer, 2011, 10, 90.

[4] Cho DC, et al. Clin Cancer Res, 2010, 16(14), 3628-3638.

[5] Zhang Y, et al. J Cell Physiol, 2012, 227(1), 35-43.

[6] Shoji K, et al. PLoS One, 2012, 7(5), e37431.

[7] Chiarini F, et al. Cancer Res, 2010, 70(20), 8097-8107.

[8] Toledo LI, et al. Nat Struct Mol Biol, 2011, 18(6), 721-727.